Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers

Expert Review of Vaccines

Volumn 13, Issue 12, 2014, Pages 1447-1462

  Tuohy, Vincent K ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Breast cancer; Cancer vaccines; Immunoprevention; T cells; Triple negative breast cancer; lactalbumin

Indexed keywords

ALPHA LACTALBUMIN; AROMATASE INHIBITOR; BEXAROTENE; CANCER VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 90; LAPATINIB; MAMMAGLOBIN A; NELIPEPIMUT S; RETIRED SELF PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; PROTEIN;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CANCER; CYSTITIS; CYTOKINE STORM; DNA IMMUNIZATION; EPSTEIN BARR VIRUS; HEALTH CARE NEED; HEPATITIS B VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERPROLACTINEMIA; INTRADUCTAL CARCINOMA; LACTATION; MASTITIS; MOLECULARLY TARGETED THERAPY; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTIPLE ORGAN FAILURE; NONHUMAN; PELVIC PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; VACCINATION; WART VIRUS; BREAST NEOPLASMS; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS;

AUTOANTIGENS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; PROTEINS;

EID: 84909647029     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.953063     Document Type: Review

References (102)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487-511
2. van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982;79(15):4718-22
3. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3
4. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). FY 2013 budget, budget authority by activity. Available from: http://obf.cancer.gov/financial/attachments/2013cj.pdf
5. Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus infection. Sex Health 2010;7(3):244-52
6. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012;10(10):681-92
7. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328(25):1797-801
8. Chang MH, Chen CJ, Lai MS, Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336(26):1855-9
9. Pattle SB, Farrell PJ. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006;6(11):1193-205
10. Beral V, Newton R, Sitas F. Human herpesvirus 8 and cancer. J Natl Cancer Inst 1999;91(17):1440-1
11. Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003;89:69-132
12. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325(16):1127-31
13. Ponta H, Günzburg WH, Salmons B, et al. Mouse mammary tumour virus: a proviral gene contributes to the understanding of eukaryotic gene expression and mammary tumorigenesis. J Gen Virol 1985;66(Pt 5):931-43
14. Holland JF, Pogo BG. Mouse mammary tumor virus-like viral infection and human breast cancer. Clin Cancer Res 2004;10(17):5647-9
15. Pogo BG, Holland JF, Levine PH. Human mammary tumor virus in inflammatory breast cancer. Cancer 2010;116(Suppl 11):2741-4
16. Szabo S, Haislip AM, Traina-Dorge V, et al. Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences. Microsc Res Tech 2005;68(3-4):209-21
17. Contreras-Galindo R, Kaplan MH, Leissner P, et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol 2008;82(19):9329-36
18. Golan M, Hizi A, Resau JH, et al. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia 2008;10(6):521-33
19. Wang-Johanning F, Rycaj K, Plummer JB, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012;104(3):189-210
20. Salmons B, Gunzburg WH. Revisiting a role for a mammary tumor retrovirus in human breast cancer. Int J Cancer 2013;133(7):1530-5
21. Old LJ. Cancer vaccine collaborative 2002: opening address. Cancer Immun 2003;3(Suppl 1):1
22. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
23. Kantoff PW, Higano CS, Shore ND, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
24. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
25. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
26. National Cancer Institute. Search for clinical trials. Available from: www.cancer.gov/clinicaltrials/search [Last accessed on 15 February 2014]
27. Hildesheim A, Herrero R, Wacholder S, Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298(7):743-53
28. Centers for Disease Control and Prevention. Immunization schedules. Available from: www.cdc.gov/vaccines/schedules/index.html?s-cid=ostltsdyk-govd-406 [Last accessed on 15 February 2014]
29. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
30. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program, Cancer Statistics Review 1975-2010. Bethesda MD, Howlader N, Noone AM, editors. Available from: http://seer.cancer.gov/csr/1975-2010/ based on November 2012 SEER data submission, posted to the SEER web site in April 2013, updated on June 14, 2013 [Last accessed on 15 February 2014]
31. Frazer IH, Lowy DR, Schiller JT. Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 2007;37(Suppl 1):S148-55
32. National Cancer Institute. FactSheet, How do cancer preventive vaccines work? Available from: www.cancer.gov/cancertopics/factsheet/Therapy/cancervaccines#r8
33. American Cancer Society, Breast Cancer Facts and Figures 2013-2014. Available from: www.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures [Last accessed on 28 July 2014]
34. Centers for Disease Control and Prevention. National Vital Statistics System. Birth Data. Available from: www.cdc.gov/nchs/births.htm
35. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Mathews TJ, Births: final data for 2012. Natl Vital Stat Rep 2012.61(1):1-72, Available from: www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62-09.pdf [Last accessed on 15 February 2014]
36. Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. Ann Med 2011;43(5):356-65
37. Jaini R, Kesaraju P, Johnson JM, et al. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 2010;16(7):799-803
38. Kesaraju P, Jaini R, Johnson JM, et al. Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination. Am J Pathol 2012;181(3):775-84
39. Setiawan VW, Feigelson HS, Henderson BE. Epidemiology and risk factors: an update. In: Bonadonna G, Hortobagyi GN, Valagussa P, editors. Textbook of breast cancer: a clinical guide to therapy. 3rd edition. Informa Healthcare/Taylor & Francis; Abingdon, UK: 2006. p. 1-16
40. Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28(12):1248-50
41. Pontén F, Gry M, Fagerberg L, et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst Biol 2009;5:337
42. The Human Protein Atlas. Available from: www.proteinatlas.org/ [Last accessed on 15 February 2014]
43. Bailey AJ, Sloane JP, Trickey BS, Ormerod MG. An immunocytochemical study of alpha-lactalbumin in human breast tissue. J Pathol 1982;137(1):13-23
44. Frantz VK, Pickren JW, Melcher GW, Auchincloss H Jr. Incidence of chronic cystic disease in so-called "normal" breasts; a study based on 225 postmortem examinations. Cancer 1951;4(4):762-83
45. Sandison AT. An autopsy study of the adult human breast: with special reference to proliferative epithelial changes of importance in the pathology of the breast. Natl Cancer Inst Monogr 1962;4:1-145
46. Hulman G, Trowbridge P, Taylor CN, et al. Oral contraceptive use and histopathology of cancerous breasts in young women. Members of the U.K. National Case-Control Study Group. J Pathol 1962;167:407-11
47. Fechner RE. Influence of oral contraceptives on breast diseases. Cancer 1977;39(6 Suppl):2764-71
48. Spratt JS, Donegan WL, Tobin G. Gross anatomy of the breast. In: Donegan WL, Spratt JS, editors. Cancer of the breast. 5th edition. Saunders; St. Louis, MO, USA: 2002. p. 29-44
49. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012;11(6-7):A465-70
50. Bellavia M, Damiano G, Palumbo VD, et al. Granulomatous mastitis during chronic antidepressant therapy: is it possible a conservative therapeutic approach? J Breast Cancer 2012;15(3):371-2
51. Lin CH, Hsu CW, Tsao TY, Chou J. Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia. Diagn Pathol 2012;7:2
52. Hassiotou F, Geddes D. Anatomy of the human mammary gland: current status of knowledge. Clin Anat 2013;26(1):29-48
53. Lemay DG, Hovey RC, Hartono SR, et al. Sequencing the transcriptome of milk production: milk trumps mammary tissue. BMC Genomics 2013;14:872
54. Medscape. Wagner CL. Human Milk and Lactation. Available from: http://emedicine.medscape.com/article/1835675-overviewupdated October 10, 2012 [Last accessed on 15 February 2014]
55. Robinson GW, McKnight RA, Smith GH, Hennighausen L. Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation. Development 1995;121(7):2079-90
56. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun 2010;34(3):J287-99
57. Motta M, Rodriguez-Perez C, Tincani A, et al. Neonates born from mothers with autoimmune disorders. Early Hum Dev 2009;85(10 Suppl):S67-70
58. Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004;115(1):3-9
59. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013;260(5):1202-14
60. Amin S, Peterson EJ, Reed AM, Mueller DL. Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. Curr Rheumatol Rep 2011;13(5):449-55
61. Gaberšček S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol 2011;7(5):697-707
62. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav 2012;62(3):263-71
63. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26(26):4282-8
64. Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi women. Breast Cancer Res Treat 2011;129(1):185-90
65. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6(1):1-6
66. ONCOMINETM database. Available from: www.oncomine.org/resource/login.html [Last accessed on 15 February 2014]
67. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490(7418):61-70
68. National Cancer Institute. The Cancer Genome Atlas. Available from: http://cancergenome.nih.gov/ Breast Invasive Carcinoma: Case Counts. Available from: https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType=BRCA&diseaseName=Breast invasive carcinoma [Last accessed on 15 February 2014]
69. Tuohy VK, Jaini R, Johnson JM, et al. Targeted vaccination against human α-lactalbumin may provide immunotherapy and immunoprevention of triple negative breast cancer [abstract 850624]. Presented at san Antonio Breast Cancer Symposium; 10-14 December 2013; San Antonio, TX, USA
70. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;10(11):CD002748
71. Milani A, Sangiolo D, Montemurro F, et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013;24(7):1740-8
72. Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 2012;8(10):1273-99
73. Sharma A, Koldovsky U, Xu S, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012;118(17):4354-62
74. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31(23):2942-62
75. Fracol M, Xu S, Mick R, et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013;20(10):3233-9
76. Disis ML, Gad E, Herendeen DR, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 2013;6(12):1273-82
77. Stanton S, Lu H, Mao J, et al. Vaccination with a panel of pre-diagnostic tumor antigens but not established tumor antigens inhibits tumor growth in TgMMTV-neu mice. Presented at san Antonio Breast Cancer Symposium-2013; 10-14 December 2013; San Antonio, TX, USA
78. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89
79. Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 2013;13(1):35-49
80. Zhao X, Bose A, Komita H, et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 2012;188(4):1782-8
81. Chi Sabins N, Taylor JL, Fabian KP, et al. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther 2013;21(10):1958-68
82. Tiriveedhi V, Fleming TP, Goedegebuure PS, et al. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat 2013;138(1):109-8
83. Zhao B, Wang Y, Wu B, et al. Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Sci Rep 2013;3:1947
84. National Breast Cancer Coalition. The Breast Cancer Deadline 2020. Artemis Project® for a Preventive Breast Cancer Vaccine. Available from: www.breastcancerdeadline2020.org/about-thedeadline/artemis-project.html [Last accessed on 15 February 2014]
85. Shen L, Sykes K, Johnston SA. Frameshift peptides as prophylactic cancer vaccine antigens. Presented at 103rd Annual Meeting of the American Association for Cancer Research; 31 March-4 April 2012; Chicago, IL, USA, Cancer Res 2012. 72(8 Suppl):abstract 1570
86. Shen L, Lee H, Sykes K, Johnston SA. Progress towards developing a universal, prophylactic cancer vaccine. Presented at 104th Annual Meeting of the American Association for Cancer Research; 6-10 April 2013; Washington, DC, USA, Cancer Res 2013. 73(8 Suppl-abstract 469
87. Lee H. Identification of neo-antigens for a cancer vaccine by transcriptome analysis. A dissertation presented in partial fulfillment of the requirements for the degree Doctor of Philosophy at Arizona State University, Tempe, AZ, USA, Johnston SA (advisor). Available from: http://repository.asu.edu/items/14514# 2012.[Last accessed on 15 February 2014]
88. Anonymous. Misguided cancer goal. Nature 2012;491(7426):637
89. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014. [Epub ahead of print]
90. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344(6184):641-5
91. Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012;118(10):2594-602
92. National Cancer Institute. ClinicalTrials. gov. Efficacy and Safety Study of Neuvax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. Available from: www.clinicaltrials.gov/show/NCT01479244 [Last accessed on 15 February 2014]
93. Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010;102(19):1496-512
94. Tchou J, Wang LC, Selven B, et al. Mesothelin, a novel immunotherapy target for triple 93gative breast cancer. Breast Cancer Res Treat 2012;133(2):799-804
95. Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One 2013;8(8):e72067
96. Wang LX, Westwood JA, Moeller M, et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 2010;70(23):9591-8
97. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4):843-51
98. Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23(35):8978-91
99. Sjödin A, Guo D, Hofer PA, et al. Mammaglobin in normal human sweat glands and human sweat gland tumors. J Invest Dermatol 2003;121(2):428-9
100. Zafrakas M, Petschke B, Donner A, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006;6:88
101. Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81(6):1297-302
102. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103(2):117-28